De fleste hudreaktioner var begrænset til administrationsstedet og resulterede kun i afbrydelse hos 2, 4% af patienterne i Prometax 9, 5 mg/ 24 timer depotplastre- behandlingsgruppen.
Most skin reactions were limited to the application site and resulted in discontinuation in only 2.4% of the patients in the Prometax 9.5 mg/ 24 h transdermal patch group.